首页
>
>
投稿咨询
微信添加科研助理

了解相关问题

加急服务
微信添加科研助理

了解相关问题

Journal of Biopharmaceutical Statistics
ISSN：1054-3406

Journal of Biopharmaceutical Statistics

J BIOPHARM STAT
学科领域：医学
是否预警：不在预警名单内
是否OA：否
录用周期：较慢,6-12周
新锐分区：医学4区
年发文量：93
影响因子：1.2
JCR分区：Q2

基本信息

《生物制药统计学杂志》是一本快速出版的杂志，讨论了统计学在生物制药研究和开发中的质量应用。现在每年出版六期，它包括以全文和短篇手稿、评论文章、精选/邀请会议论文、短篇文章和致编辑的信的形式对直接适用于生物制药研究的统计方法学的阐述。该杂志涵盖了对生物统计专业重要的及时和具有启发性的主题：药物、器械和生物学研究与开发;药物筛选和药物设计;药理活性评估;药物配方和放大;临床前安全性评估;生物利用度、生物等效性和药代动力学; I、II和III期临床开发，包括复杂的创新设计;临床安全性的上市前批准评估;上市后监测;大数据和人工智能及应用。
1054-3406SCIE/Scopus收录
1.2
点击查看最新影响趋势>
1.3
新
2026年3月发布
点击查看历史分区趋势    >
大类学科小类学科Top期刊综述期刊
医学4区
PHARMACOLOGY & PHARMACY 药学
4区
STATISTICS & PROBABILITY 统计学与概率论
4区
否
N/A
新
WOS期刊SCI分区  2024-2025最新升级版
按JIF指标学科分区收集子录JIF分区JIF排名百分位
学科：PHARMACOLOGY & PHARMACY
SCIE
Q4
291/352
学科：STATISTICS & PROBABILITY
SCIE
Q2
79/169
按JCR指标学科分区收集子录JCR分区JCR排名百分位
学科：PHARMACOLOGY & PHARMACY
SCIE
Q3
214/353
学科：STATISTICS & PROBABILITY
SCIE
Q2
84/169
43
93
点击查看年发文量趋势图>
-容易较慢,6-12周-医学-统计学与概率论
16.7%
点击查看自引率趋势图>
时间预警情况
2026年03月发布的新锐学术版不在预警名单中
2025年03月发布的2025版不在预警名单中
2024年02月发布的2024版不在预警名单中
2023年01月发布的2023版不在预警名单中
2021年12月发布的2021版不在预警名单中
2020年12月发布的2020版不在预警名单中
97.85%5%-
CiteScore：2.10
SJR：0.565
SNIP：0.784
学科类别分区排名百分位
大类：Mathematics
小类：Statistics and Probability
Q3
151 / 293
大类：Mathematics
小类：Pharmacology (medical)
Q3
178 / 275
大类：Mathematics
小类：Pharmacology
Q3
232 / 321

期刊高被引文献

Randomized dose-escalation designs for drug combination cancer trials with immunotherapy
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2018.1535503
The i3+3 design for phase I clinical trials
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1636811
Partial Youden index and its inferences
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2018.1535502
Good statistical practice in utilizing real-world data in a comparative study for premarket evaluation of medical devices
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1632880
Estimation of delay time in survival data with delayed treatment effect
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2018.1534857
Design of randomized controlled confirmatory trials using historical control data to augment sample size for concurrent controls
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2018.1559853
Commentary on “Applying CHW method to 2-in-1 design: gain or lose”
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1634088
Randomization-based analysis of covariance for inference in the sequential parallel comparison design
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1633660
Simulation optimization for Bayesian multi-arm multi-stage clinical trial with binary endpoints
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1577682
Semi-parametric Bayesian regression for subgroup analysis in clinical trials
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1572613
Bayesian sample size determination for longitudinal studies with continuous response based on different scientific questions of interest
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2018.1535501
Simultaneous confidence interval methods for analytical similarity assessment
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1657142
Look before you leap: systematic evaluation of tree-based statistical methods in subgroup identification
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1584204
Methods and applications of percentile estimation
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1632872
Utilizing shared internal control arms and historical information in small-sized platform clinical trials
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1657132
Selection of the optimal personalized treatment from multiple treatments with multivariate outcome measures
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1684304
A comparison of stochastic programming methods for portfolio level decision-making
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1684307
Optimal adaptive single-arm phase II trials under quantified uncertainty
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1609016
Sensitivity analysis for the generalized shared-parameter model framework
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1632875
ASIED: a Bayesian adaptive subgroup-identification enrichment design
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1696356
Demonstrating effectiveness or demonstrating not ineffectiveness – A potential solution for rare disease drug product development?
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1657137
Sample size calculation and blinded recalculation for analysis of covariance models with multiple random covariates
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1632871
A latent class based imputation method under Bayesian quantile regression framework using asymmetric Laplace distribution for longitudinal medication usage data with intermittent missing values
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1684306
Interval estimators of relative potency in toxicology and radiation countermeasure studies: comparing methods and experimental designs
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2018.1535500
Studying treatment-effect heterogeneity in precision medicine through induced subgroups
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1579220
Probability monitoring procedures for sample size determination
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1657139
Sample size computation in phase II designs combining the A’Hern design and the Sargent and Goldberg design
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1641817
The use of 95% CI or 90% CI for drug product development — a controversial issue?
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1657141
Adaptive clinical endpoint bioequivalence studies with sample size re-estimation based on a nuisance parameter
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1657143
Benefit-risk assessment for binary diagnostic tests
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1657135
Comment on “Efficient statistical inference for a parallel study with missing data by using an exact method” by Shan et al. (2019)
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1641818
Comparisons of global tests on intersection hypotheses and their application in matched parallel gatekeeping procedures
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1696355
Group sequential design for historical control trials using error spending functions
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1684305
Estimation on conditional restricted mean survival time with counting process
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1657129
Approximate confidence limit for the reference scaled bioequivalence with a parallel design
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1657438
Letter to the editor: Arithmetic error in Bland, J. M., & Altman, D. G. (2007). Agreement between methods of measurement with multiple observations per individual
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1572618
A reproducibility probability-based bias-adjustment approach on the specification of non-inferiority margin using historical data
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1632879
Response adaptive randomization procedures in seamless phase II/III clinical trials
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1657439
Comparing methods for clinical investigator site inspection selection: a comparison of site selection methods of investigators in clinical trials
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1657134
Referees for Volume 29
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1691360
Comparison of balancing scores using the ANCOVA approach for estimating average treatment effect: a simulation study
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2018.1559855
Marginalized models for right-truncated and interval-censored time-to-event data
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1607366
A reflection on the causal interpretation of individual-level surrogacy
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1579221
Rayleigh-half normal distribution for modeling tooth movement data
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1684312
Performance of randomization-based causal methods with and without integrating external data sources for adjusting overall survival in case of extensive treatment switches in placebo-controlled randomized oncology phase 3 trials
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1695625
Innovative Thinking on Endpoint Selection in Clinical Trials
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1657140
Homogeneity assessment for pivotal medical device clinical studies
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1657131
High dimensional surrogacy: computational aspects of an upscaled analysis
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1657128
Bayesian approach for cure models with a change-point based on covariate threshold: application to breast cancer data
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2019.1632877
Interim analysis of binary outcome data in clinical trials: a comparison of five estimators
来源期刊：Journal of Biopharmaceutical StatisticsDOI：10.1080/10543406.2018.1559852

相关文章

Materials Today Bio解析：IF=8.7，8天初审
2025-11-25
《ZEITSCHRIFT FUR GEBURTSHILFE UND NEONATOLOGIE》德国老牌产科期刊免版面费、非预警，毕业保底首选！
2025-11-25
Journal of Multidisciplinary Healthcare：IF= 2.4，中科院3区，JCR Q2，多学科综合医学开放获取期刊，应用性强，审稿迅速，编辑反馈专业！
2025-10-15
European Journal of Medical Genetics：IF= 1.7，中科院4区，JCR Q3，医学遗传学期刊，涵盖分子遗传学、临床基因诊断与罕见病研究，欧洲地区影响力较稳，国际传播适中！
2025-10-15
ANNALS OF ONCOLOGY：中科院1区，肿瘤学，接受率为25%
2025-10-15
Journal of Cystic Fibrosis：权威官方背景，高影响力，整体周期约 3 个月，部分 1 天录用
2025-10-15
JOURNAL OF INHERITED METABOLIC DISEASE：影响因子平稳，学术认可度高，年发文稳定，4个月录用
2025-10-15
JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE：自引风险小，审稿周期短，发表难度低，但if持续下降
2025-10-15
Neurobiology of Stress：中科院 2 区，认可度高，国人发文第二，机会公平
2025-10-15
NATURE REVIEWS DRUG DISCOVERY：中科院1区，生物工程与应用微生物，药学，接受率为21%
2025-10-15

期刊推荐

ACSMS HEALTH & FITNESS JOURNAL封面

ACSMS HEALTH & FITNESS JOURNAL

学科领域：医学
影响因子：1.8
中科院分区： 4区
ACTA BIOQUIMICA CLINICA LATINOAMERICANA封面

ACTA BIOQUIMICA CLINICA LATINOAMERICANA

学科领域：医学
影响因子：0.1
中科院分区： 4区
Acta Cardiologica Sinica封面

Acta Cardiologica Sinica

学科领域：医学
影响因子：1.8
中科院分区： 4区
Acta Chirurgiae Orthopaedicae et Traumatologiae Cechoslovaca封面

Acta Chirurgiae Orthopaedicae et Traumatologiae Cechoslovaca

学科领域：医学
影响因子：0.4
中科院分区： 4区
论文发表 2-4个月录用 7500+文章录用 不成功可退款
新
2026年3月发布（新锐分区）
大类学科小类学科Top期刊综述期刊
医学4区
PHARMACOLOGY & PHARMACY 药学
4区
STATISTICS & PROBABILITY 统计学与概率论
4区
否
N/A
2025年3月升级版
大类学科小类学科Top期刊综述期刊
医学4区
STATISTICS & PROBABILITY 统计学与概率论
3区
PHARMACOLOGY & PHARMACY 药学
4区
否
否
2023年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学4区
PHARMACOLOGY & PHARMACY 药学
4区
STATISTICS & PROBABILITY 统计学与概率论
4区
否
否